Document Format Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
1 | REGISTRATION STATEMENT | fs42022a2_biotechacq.htm iXBRL | S-4/A | 14738184 |
2 | OPINION OF ELLENOFF GROSSMAN & SCHOLE LLP | fs42022a2ex5-1_biotechacq.htm | EX-5.1 | 23788 |
3 | TAX OPINION OF ELLENOFF GROSSMAN & SCHOLE LLP | fs42022a2ex8-1_biotechacq.htm | EX-8.1 | 11524 |
4 | OFFER LETTER, DATED AS OF JULY 18, 2016, BY AND BETWEEN BLADE THERAUEPTICS, INC. | fs42022a2ex10-15_biotechacq.htm | EX-10.15 | 30977 |
5 | OFFER LETTER, DATED AS OF FEBRUARY 1, 2021, BY AND BETWEEN BLADE THERAPEUTICS, I | fs42022a2ex10-16_biotechacq.htm | EX-10.16 | 24351 |
6 | OFFER LETTER, DATED AS OF APRIL 19, 2017, BY AND BETWEEN BLADE THERAPEUTICS, INC | fs42022a2ex10-17_biotechacq.htm | EX-10.17 | 15566 |
7 | OFFER LETTER, DATED AS OF SEPTEMBER 30, 2016, BY AND BETWEEN BLADE THERAPEUTICS, | fs42022a2ex10-18_biotechacq.htm | EX-10.18 | 23083 |
8 | AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT | fs42022a2ex10-19_biotechacq.htm | EX-10.19 | 13219 |
9 | AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT | fs42022a2ex10-20_biotechacq.htm | EX-10.20 | 12471 |
10 | AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT | fs42022a2ex10-21_biotechacq.htm | EX-10.21 | 12413 |
11 | AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT | fs42022a2ex10-22_biotechacq.htm | EX-10.22 | 13264 |
12 | CONSENT OF MARCUM LLP | fs42022a2ex23-1_biotechacq.htm | EX-23.1 | 2566 |
13 | CONSENT OF ERNST AND YOUNG LLP, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR BLADE | fs42022a2ex23-2_biotechacq.htm | EX-23.2 | 1917 |
14 | CONSENT OF WENDYE ROBBINS TO BE NAMED AS A DIRECTOR | fs42022a2ex99-2_biotechacq.htm | EX-99.2 | 2781 |
15 | CONSENT OF MARK TIMNEY TO BE NAMED AS A DIRECTOR | fs42022a2ex99-3_biotechacq.htm | EX-99.3 | 2756 |
16 | CONSENT OF LLOYD KLICKSTEIN TO BE NAMED AS A DIRECTOR | fs42022a2ex99-4_biotechacq.htm | EX-99.4 | 2692 |
17 | CONSENT OF JAMES SCOPA TO BE NAMED AS A DIRECTOR | fs42022a2ex99-5_biotechacq.htm | EX-99.5 | 2752 |
18 | CONSENT OF LUKE EVNIN TO BE NAMED AS A DIRECTOR | fs42022a2ex99-6_biotechacq.htm | EX-99.6 | 2753 |
19 | CONSENT OF JOHN A. HOHNEKER, M.D. TO BE NAMED AS A DIRECTOR | fs42022a2ex99-7_biotechacq.htm | EX-99.7 | 2793 |
20 | CONSENT OF CARL GOLDFISCHER, M.D. TO BE NAMED AS A DIRECTOR | fs42022a2ex99-8_biotechacq.htm | EX-99.8 | 2830 |
21 | GRAPHIC | ex10-15_001.jpg | GRAPHIC | 8891 |
22 | GRAPHIC | ex10-16_001.jpg | GRAPHIC | 3598 |
23 | GRAPHIC | ex10-17_001.jpg | GRAPHIC | 3600 |
24 | GRAPHIC | ex10-18_001.jpg | GRAPHIC | 14480 |
25 | GRAPHIC | ex10-19_001.jpg | GRAPHIC | 7447 |
26 | GRAPHIC | ex10-19_002.jpg | GRAPHIC | 6620 |
27 | GRAPHIC | ex10-20_001.jpg | GRAPHIC | 7447 |
28 | GRAPHIC | ex10-20_002.jpg | GRAPHIC | 6620 |
29 | GRAPHIC | ex10-21_001.jpg | GRAPHIC | 7447 |
30 | GRAPHIC | ex10-21_002.jpg | GRAPHIC | 6620 |
31 | GRAPHIC | ex10-22_001.jpg | GRAPHIC | 7447 |
32 | GRAPHIC | ex10-22_002.jpg | GRAPHIC | 6620 |
33 | GRAPHIC | timage_001.jpg | GRAPHIC | 332585 |
34 | GRAPHIC | timage_002.jpg | GRAPHIC | 497065 |
35 | GRAPHIC | timage_003.jpg | GRAPHIC | 234595 |
36 | GRAPHIC | timage_004.jpg | GRAPHIC | 236924 |
37 | GRAPHIC | timage_005.jpg | GRAPHIC | 281576 |
38 | GRAPHIC | timage_008.jpg | GRAPHIC | 634866 |
39 | GRAPHIC | timage_009.jpg | GRAPHIC | 456998 |
40 | GRAPHIC | timage_010.jpg | GRAPHIC | 202698 |
41 | GRAPHIC | timage_011.jpg | GRAPHIC | 366569 |
42 | GRAPHIC | timage_012.jpg | GRAPHIC | 523511 |
43 | GRAPHIC | timage_013.jpg | GRAPHIC | 651939 |
44 | GRAPHIC | timage_014.jpg | GRAPHIC | 402930 |
45 | GRAPHIC | timage_015.jpg | GRAPHIC | 394241 |
46 | GRAPHIC | timage_016.jpg | GRAPHIC | 613108 |
47 | GRAPHIC | timage_017.jpg | GRAPHIC | 506892 |
48 | GRAPHIC | timage_018.jpg | GRAPHIC | 307049 |
49 | GRAPHIC | timage_019.jpg | GRAPHIC | 408186 |
50 | GRAPHIC | timage_020.jpg | GRAPHIC | 548620 |
51 | GRAPHIC | timage_021.jpg | GRAPHIC | 540532 |
52 | GRAPHIC | timage_022.jpg | GRAPHIC | 544084 |
53 | GRAPHIC | timage_023.jpg | GRAPHIC | 581089 |
54 | GRAPHIC | timage_024.jpg | GRAPHIC | 472248 |
55 | GRAPHIC | tvantage_header.jpg | GRAPHIC | 253198 |
56 | GRAPHIC | tvantage_footer1.jpg | GRAPHIC | 44525 |
57 | GRAPHIC | tvantage_footer11.jpg | GRAPHIC | 44525 |
58 | GRAPHIC | tvantage_sig.jpg | GRAPHIC | 57696 |
Complete submission text file | 0001213900-22-020222.txt | 52881894 |
Data Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
59 | XBRL SCHEMA FILE | biot-20211231.xsd | EX-101.SCH | 143802 |
60 | XBRL CALCULATION FILE | biot-20211231_cal.xml | EX-101.CAL | 44256 |
61 | XBRL DEFINITION FILE | biot-20211231_def.xml | EX-101.DEF | 618246 |
62 | XBRL LABEL FILE | biot-20211231_lab.xml | EX-101.LAB | 961200 |
63 | XBRL PRESENTATION FILE | biot-20211231_pre.xml | EX-101.PRE | 608243 |
155 | EXTRACTED XBRL INSTANCE DOCUMENT | fs42022a2_biotechacq_htm.xml | XML | 3468884 |
IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: S-4/A | Act: 33 | File No.: 333-263577 | Film No.: 22830736
SIC: 2834 Pharmaceutical Preparations